Cargando…

Regional Chemotherapy Is a Valuable Second-Line Approach in Metastatic Esophageal Cancer after Failure to First-Line Palliative Treatment

Background: Therapeutic options in metastatic esophageal cancer (EC) are limited with unsatisfactory results. We evaluated the efficacy of regional chemotherapy (RegCTx) approach in diffuse metastatic EC using arterial infusion (AI), upper abdominal perfusion (UAP) and isolated-thoracic perfusion (I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vashist, Yogesh, Aigner, Kornelia, Dam, Miriam, Gailhofer, Sabine, Aigner, Karl R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316981/ https://www.ncbi.nlm.nih.gov/pubmed/35877246 http://dx.doi.org/10.3390/curroncol29070386

Ejemplares similares

Therapeutic Effect of Regional Chemotherapy in Diffuse Metastatic Cholangiocarcinoma
por: Vashist, Yogesh, et al.
Publicado: (2022)

Efficacy of Regional Chemotherapy Approach in Peritoneal Metastatic Gastric Cancer
por: Aigner, Kornelia, et al.
Publicado: (2021)

Intra-arterial infusion chemotherapy versus isolated upper abdominal perfusion for advanced pancreatic cancer: a retrospective cohort study on 454 patients
por: Aigner, Karl R., et al.
Publicado: (2019)

Hypoxic Isolated Abdominal Perfusion (HAP) chemotherapy for non-operable advanced staged ovarian cancer with peritoneal carcinosis: an experience in 45 platinum-refractory ovarian cancer patients
por: Aigner, Karl Reinhard, et al.
Publicado: (2019)

Carotid artery infusion via implantable catheters for squamous cell carcinoma of the tonsils
por: Aigner, Karl Reinhard, et al.
Publicado: (2018)

Hypoxic isolated abdominal perfusion breaks through chemoresistance in recurrent FIGO stage IIIC and IV ovarian cancer
por: Aigner, Karl R., et al.
Publicado: (2021)

Case report: Extended Isolated Stopflow Limb Infusion (EISLI) for highly malignant osteosarcoma - complete pathological tumor remission and implantation of a knee joint prosthesis
por: Aigner, Kornelia, et al.
Publicado: (2023)

Isolated thoracic perfusion with chemofiltration for progressive malignant pleural mesothelioma
por: Aigner, Karl Reinhard, et al.
Publicado: (2017)

Tumor response and the quality of life after isolated hypoxic pelvic perfusion for advanced G3 cervical cancer: A case series
por: Aigner, Karl R., et al.
Publicado: (2020)

Short-term intra-arterial infusion chemotherapy for head and neck cancer patients maintaining quality of life
por: Aigner, Karl R., et al.
Publicado: (2018)

Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure
por: Kobayashi, Noritoshi, et al.
Publicado: (2017)

Complete Radiologic Response of Metastatic Pancreatic Ductal Adenocarcinoma to Microwave Ablation Combined with Second-Line Palliative Chemotherapy
por: Blomstrand, Hakon, et al.
Publicado: (2020)

Clinical Benefit of Second-Line Palliative Chemotherapy in Advanced Soft-Tissue Sarcoma
por: Minchom, Anna, et al.
Publicado: (2010)

Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer
por: Gränsmark, Emma, et al.
Publicado: (2020)

Second-line docetaxel-based chemotherapy after failure of fluorouracil-based first-line treatment for advanced esophageal squamous cell carcinoma
por: Song, Zhengbo, et al.
Publicado: (2014)

Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer
por: Blomstrand, Hakon, et al.
Publicado: (2021)

Irinotecan plus fluorouracil‐based regimen as second or third‐line chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma
por: Wang, Xi, et al.
Publicado: (2015)

Gemcitabine Plus Vinorelbine as Second-Line Therapy in Patients With Metastatic Esophageal Cancer Previously Treated With Platinum-Based Chemotherapy
por: Wang, Yue-shen, et al.
Publicado: (2016)

Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
por: Cai, Hongfu, et al.
Publicado: (2021)

Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
por: Shi, Fenghao, et al.
Publicado: (2022)

Approaching 10 years disease-free survival after isolated thoracic perfusion for advanced stage IV tonsil carcinoma: A case report
por: Aigner, Karl R., et al.
Publicado: (2020)

Multicenter phase II study of apatinib treatment for metastatic gastric cancer after failure of second-line chemotherapy
por: Ruan, Hanguang, et al.
Publicado: (2017)

Decision aids for second-line palliative chemotherapy: a randomised phase II multicentre trial
por: Oostendorp, Linda J. M., et al.
Publicado: (2017)

Second-line chemotherapy for the treatment of metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy: a network meta-analysis
por: Citterio, Chiara, et al.
Publicado: (2018)

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
por: Yamamoto, Shun, et al.
Publicado: (2021)

Survival Outcomes Associated with First and Second-Line Palliative Systemic Therapies in Patients with Metastatic Bladder Cancer
por: Beigi, Arshia, et al.
Publicado: (2021)

Patients’ Preferences for Information About the Benefits and Risks of Second-Line Palliative Chemotherapy and Their Oncologist’s Awareness of These Preferences
por: Oostendorp, Linda J. M., et al.
Publicado: (2015)

Efficacy of cisplatin combined with vinorelbine as second- or higher-line palliative chemotherapy in patients with advanced ovarian cancer
por: Yeon, Sang Hoon, et al.
Publicado: (2023)

Impact of palliative therapies in metastatic esophageal cancer patients not receiving chemotherapy
por: Kim, Sungjin, et al.
Publicado: (2020)

Genotyping and outcomes of presumptive second line ART failure cases switched to third line or maintained on second line ART in Mumbai, India
por: Gill, Naresh, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
por: Lin, Ying-Tao, et al.
Publicado: (2021)

Efficacy of cisplatin combined with topotecan in patients with advanced or recurrent ovarian cancer as second- or higher-line palliative chemotherapy
por: Lee, Myung-Won, et al.
Publicado: (2020)

Qualitative study of patients’ decision-making when accepting second-line treatment after failure of first-line chemotherapy
por: Pujol, Jean-Louis, et al.
Publicado: (2018)

Cost-Effectiveness of Second-Line Chemotherapy/Biologics among Elderly Metastatic Colon Cancer Patients
por: Zheng, Zhiyuan, et al.
Publicado: (2014)

FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study
por: Zaanan, Aziz, et al.
Publicado: (2014)

Evaluation of vinorelbine-based chemotherapy as the second or further-line treatment in patients with metastatic breast cancer
por: Cybulska-Stopa, Bożena, et al.
Publicado: (2013)

The prognostic value of D-dimer levels in metastatic osteosarcoma patients treated with second-line chemotherapy
por: Huang, Yujing, et al.
Publicado: (2016)

Exceptional Response to Second-Line Gemcitabine/Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma
por: Bukhari, Nedal, et al.
Publicado: (2021)

Cell lines: Valuable tools or useless artifacts
por: Kaur, Gurvinder, et al.
Publicado: (2012)

Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life
por: Van Cutsem, E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dj44sqm84385bm0v0v12o9qofg